{{Drugbox
| verifiedrevid = 443805396
| IUPAC_name = 8-[(''E'')-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1''H''-purine-2,6-dione
| image = Istradefylline.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 5608
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 155270-99-8
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 5311037
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4470574
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2GZ0LIK7T4
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04641
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 431770

<!--Chemical data-->
| chemical_formula =  
| C=20 | H=24 | N=4 | O=4 
| molecular_weight = 384.429 g/mol
| smiles = O=C2N(c1nc(n(c1C(=O)N2CC)C)\C=C\c3ccc(OC)c(OC)c3)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IQVRBWUUXZMOPW-PKNBQFBNSA-N
}}

'''Istradefylline''' ('''KW-6002''') is a selective [[receptor antagonist|antagonist]] at the [[Adenosine A2a receptor|A<sub>2A</sub> receptor]]. It has been found to be useful in the treatment of [[Parkinson's disease]].<ref name="pmid18306243">{{cite journal | author = Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD | title = Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005) | journal = Annals of Neurology | volume = 63 | issue = 3 | pages = 295â€“302 | year = 2008 | pmid = 18306243 | doi = 10.1002/ana.21315 }}</ref> Istradefylline reduces [[dyskinesia]] resulting from long-term treatment with classical [[antiparkinson drug]]s such as [[levodopa]]. Istradefylline is an analog of [[caffeine]].

== References ==
{{Reflist}}


{{Adenosinergics}}

[[Category:Adenosine receptor antagonists]]
[[Category:Xanthines]]
[[Category:Phenol ethers]]
[[Category:Alkene derivatives]]


{{nervous-system-drug-stub}}